Molecular Pituitary Imaging Using 18F-FET PET

Trial Title: Molecular Pituitary Imaging Using 18F-FET PET

NCT ID: NCT06584123

Condition: Pituitary Adenoma

Conditions: Official terms:
Adenoma
Pituitary Neoplasms
Pituitary Diseases

Conditions: Keywords:
Molecular pituitary imaging
Functional pituitary imaging
18F-FET PET

Study type: Interventional

Study phase: N/A

Overall status: Not yet recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Intervention model description: Patient's who have previously undergone 11C-Methionine PET during routine clinical care will be invited to undergo 18F-Fluoro-ethyl-tyrosine PET (FET PET).

Primary purpose: Diagnostic

Masking: None (Open Label)

Intervention:

Intervention type: Diagnostic Test
Intervention name: 18F-Fluoro-ethyl-tyrosine (FET) PET
Description: 18F-Fluoro-ethyl-tyrosine PET study of the pituitary
Arm group label: Study cohort

Summary: The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.

Detailed description: Up to 20 patients with pituitary adenomas (PA) who have previously undergone 11C-methionine PET (Met-PET) as part of routine clinical care will undergo 18F-fluoroethyltyrosine PET (FET-PET). Patients with newly diagnosed PA or residual/recurrent pituitary tumours following previous treatment will be eligible for recruitment to the study. Quantitative and qualitative analyses will be performed to assess whether MET-PET and FET-PET yield comparable findings in patients with newly diagnosed or recurrent PA.

Criteria for eligibility:
Criteria:
Inclusion criteria - Participant is willing and able to give informed consent for participation in the study - Male or female, age 18 or above - Presence of pituitary adenoma suspected on the basis of clinical/biochemical and/or radiological findings - Previous 11C-Met-PET/CT Exclusion criteria - Inability to give informed consent - Pregnancy or suspected pregnancy - Inability to lie supine for 30-60 minutes - Patient body habitus above scanner dimensions - Known allergy to intravenous radiographic contrast agents

Gender: All

Minimum age: 18 Years

Maximum age: 100 Years

Healthy volunteers: No

Start date: September 3, 2024

Completion date: December 31, 2026

Lead sponsor:
Agency: University of Cambridge
Agency class: Other

Collaborator:
Agency: Cambridge University Hospitals NHS Foundation Trust
Agency class: Other

Source: University of Cambridge

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06584123